HGH (Somatropin) vs Sermorelin

HGH (Somatropin)

Recombinant human growth hormone — the actual hormone itself, not a secretagogue. Powerful for body recomposition, with side effects that scale unmistakably with dose.

Best for

Best when you want the strongest, most predictable GH and IGF-1 elevation and accept the cost and feedback suppression.

Sermorelin

The oldest GHRH analogue still in widespread use — the first 29 amino acids of natural GHRH, unmodified. Pulses the pituitary in line with the body's natural sleep-onset GH window.

Best for

Best when you want to stimulate your own GH within physiologic limits, gentler and with the axis intact.

HGH (Somatropin)

Recombinant somatropin is FDA- and EMA-approved for adult growth hormone deficiency, pediatric short stature, and HIV-associated wasting. The drug itself is well-characterised; the body of clinical literature spans four decades. The off-label use in non-deficient adults for body recomposition and anti-aging is not what the approval covers — that is an extrapolation from on-label pharmacology, supported by smaller trials in healthy older adults (Rudman 1990 is the famous one, and several follow-ups since) but not by a large RCT base in healthy populations.

Sermorelin

Sermorelin held FDA approval for paediatric GH deficiency from 1997 to 2008, when it was withdrawn from the US market for commercial — not safety or efficacy — reasons. The paediatric trial base is real and was good enough to clear regulatory review. Adult body-recomposition and anti-aging use is off-label and supported by smaller open-label work and the on-label pharmacology rather than a dedicated RCT base in healthy adults. The chronic safety record is reassuring across 25+ years of clinical and grey-market use.